Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A phase 2 trial of Sonrotoclax in non-Hodgkin lymphoma and chronic lymphocytic leukaemia, run by BeiGene, active and no longer recruiting.
Overview
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma is a phase 2 interventional study registered as NCT05479994 by BeiGene, with 100 participants enrolled, started 2022-10-25 and due to reach its primary completion in 2025-01-24. Interventions recorded: BGB-11417.
Similar pages
not linked directly; found by shared links- TrialA Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
Shares Sonrotoclax, BeOne Medicines (formerly BeiGene), Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Shares Sonrotoclax, BeOne Medicines (formerly BeiGene), Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Shares Sonrotoclax, BeOne Medicines (formerly BeiGene), Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
Shares Sonrotoclax, BeOne Medicines (formerly BeiGene) and the tag pipeline.
- TrialA Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Shares Sonrotoclax, BeOne Medicines (formerly BeiGene), Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study of BGB-11417 in Participants With Myeloid Malignancies
Shares Sonrotoclax, BeOne Medicines (formerly BeiGene) and the tag pipeline.
- TrialA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Shares BeOne Medicines (formerly BeiGene), Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Shares Non-Hodgkin lymphoma (all types), Chronic lymphocytic leukaemia and the tag pipeline.